Skip to main content

Table 1 Clinical performance of CLART4S and MGP-PCR in SurePath and ThinPrep cervical cancer screening samples

From: Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening

Specificity and Sensitivity (95% Confidence Interval)
  SurePath ThinPrep
Accuracy parameter CLART4S MGP-PCR CLART4S MGP-PCR
Specificity <CIN2 1074/1184
(0.91; 0.89–0.92)
1078/1184
(0.91; 0.89–0.93)
1096/1169
(0.94; 0.92–0.95)
1013/1169
(0.87; 0.85–0.89)
Relative Specificity 1.0
(0.97–1.02)
1.0 1.1
(1.05–1.11)
1.0
Sensitivity ≥CIN2 73/81
(0.90; 0.81–0.96)
75/81
(0.93; 0.85–0.97)
78/80
(0.98; 0.91–1.00)
80/80
(1.00; 0.95–1.00)
Relative sensitivity 0.97
(0.89–1.07)
1.0 0.98
(0.94–1.01)
1.0